Sudarshan K Sharma MD Limted-Gynecologic Oncology

Hinsdale, Illinois 60521

0 studies enrolling now · 23 studies all time

What they study most

Adult Type Ovarian Granulosa Cell Tumor, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

Studies at this site

• Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma — Stopped early
• Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection — Status unconfirmed
• Paclitaxel in Treating Patients With Ovarian Stromal Cancer — Completed
• Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer — Completed
• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer — Completed
• Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer — Completed
• Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy — Completed
• Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer — Completed
• Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer — Completed
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer — Completed
• Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer — Completed
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer — Completed
• Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus — Completed
• Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary — Completed
• Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer — Completed
• Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer — Completed
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer — Stopped early
• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy — Stopped early
• Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer — Completed
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer — Completed
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Status unconfirmed
• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer — Completed